Tularemia: Next-Step Management When First-Line Antimicrobial Therapy Fails to Resolve Fever
Clinical Scenario
A patient with tularemia who is receiving first-line antimicrobial therapy has not achieved defervescence — fever has not resolved within approximately four days of starting treatment. This inadequate response signals that an alternative antimicrobial strategy is needed.
Previous Treatment — Inadequate Response
First-line antimicrobial monotherapy (ciprofloxacin, levofloxacin, gentamicin, or doxycycline) did not achieve its primary goal: defervescence within approximately four days of treatment initiation.
Treatment Approach — This Protocol
When first-line drugs are unavailable or contraindicated, the protocol designates alternative agents drawn from distinct antimicrobial classes — including an alternative tetracycline, alternative fluoroquinolones, and alternative aminoglycosides.
Complete agent selection, weight- and age-based dosing, and administration details are in the full protocol.
References
- Although doxycycline has replaced tetracycline as first-line treatment of tularemia in adults, tetracycline remains an acceptable second-line agent.
- For example, moxifloxacin and ofloxacin are listed as alternative fluoroquinolone options and amikacin, tobramycin, and plazomicin are included as alternative aminoglycoside options.
- Other aminoglycosides, namely amikacin, tobramycin, and plazomicin, can be considered as alternative treatment options if gentamicin is contraindicated and first-line antimicrobial drugs are not available.
View source ↗